E. Bleuler, A. Viallard, and H. Ey, Dementia praecox ou Groupe des schizophr. nies. Paris, 1993.

C. Demily and N. Franck, Schizophre?nie: diagnostic et prise en charge. Issy-les-Moulineaux, 2013.

N. Franck and T. F. , Pharmacologie et mode d'action des neuroleptiques. EMC - Psychiatr, pp.282-99, 2005.
DOI : 10.1016/s0246-1072(05)32572-7

Q. Debray, B. Granger, and F. Azais, Psychopathologie de l'adulte. Issy-les-Moulineaux, 2010.

H. Guide-affection, . De, and . Durée-juin, Available from, SCHIZOPHRÉNIES [Internet], 2007.

. American-psychiatric-association, M. Crocq, and J. Guelfi, DSM-IV-TR manuel diagnostique et statistique des troubles mentaux, 2004.

M. Saoud and T. Amato, La schizophre?nie de l'adulte: des causes aux traitements, 2006.

M. Krebs, Dossiers d'information schizophrenie [Internet]. 2014 Available from: http://www.inserm.fr/thematiques/neurosciences-sciences-cognitives-neurologie- psychiatrie/dossiers-d-information/schizophrenie

B. Martin and N. Franck, La reme?diation cognitive : un nouvel outil de soin pour la schizophrénie. Perspect Psy, pp.7-13, 2012.
DOI : 10.1051/ppsy/2011511007

J. Hegarty, R. Baldessarini, M. Tohen, C. Waternaux, and G. Oepen, One hundred years of schizophrenia: A meta-analysis of the outcome literature, Schizophrenia Research, vol.9, issue.2-3, 1994.
DOI : 10.1016/0920-9964(93)90221-4

V. Kapsambelis and F. Laugier, Manuel de psychiatrie clinique et psychopathologique de l'adulte. Paris: Puf; 2012

F. Schürhoff and A. Szöke, Traduction des recommandations pour le traitement biologique des schizophre?nies Chapitre I : traitement de la phase aiguë [Internet]. The World Federation of Societies of Biological Psychiatry (WFSBP); Available from

D. Tsoi, M. Hunter, and P. Woodruff, History, aetiology, and symptomatology of schizophrenia, Psychiatry, vol.7, issue.10, pp.404-413, 2008.
DOI : 10.1016/j.mppsy.2008.07.010

. E. Slater and V. Cowie, The Genetics of Mental Disorder, 1971.

. Modèle, Fondation des maladies mentales Available from

. Antipsychotique, Available from: http://www.psychologies.com/Dico-Psycho/Antipsychotique 24, 2014.

L. Lilly, Schizophre?nie : prise en charge [Internet] Available from

W. Carpenter and J. Koenig, The evolution of drug development in schizophrenia: past issues and future opportunities. Neuropsychopharmacol Off Publ Am Coll Neuropsychopharmacol, pp.2061-79, 2008.

J. Pr and . Senon, Les neuroleptiques [Internet] Universite?deUniversite?de Poitiers : faculte?defaculte?de me?decine Available from: http://www.schizophrenies.fr/PDF/SENON_CSCT_neuroleptiques.pdf 29, La Commission européenne approuve le XEPLION(R) pour le traitement de la schizophrénie [Internet], 2002.

P. Connell, Amphetamine psychosis monographs, Maudsley, issue.5, 1958.

D. Kim, M. Maneen, and S. Stahl, Building a better antipsychotic: Receptor targets for the treatment of multiple symptom dimensions of schizophrenia, Neurotherapeutics, vol.100, issue.1, pp.78-85, 2009.
DOI : 10.1073/pnas.1835612100

O. Howes, J. Kambeitz, E. Kim, D. Stahl, M. Slifstein et al., The Nature of Dopamine Dysfunction in Schizophrenia and What This Means for Treatment, Archives of General Psychiatry, vol.69, issue.8, 2009.
DOI : 10.1001/archgenpsychiatry.2012.169

J. Brezun and A. Daszuta, Depletion in serotonin decreases neurogenesis in the dentate gyrus and the subventricular zone of adult rats, Neuroscience, vol.89, issue.4, pp.999-1002, 1999.
DOI : 10.1016/S0306-4522(98)00693-9

H. Meltzer and B. Massey, The role of serotonin receptors in the action of atypical antipsychotic drugs, Current Opinion in Pharmacology, vol.11, issue.1, pp.59-67, 2011.
DOI : 10.1016/j.coph.2011.02.007

F. Eustache and . L-'hippocampe-ultime-rempart-de-la-me?moire, Available from, 2006.

P. Seeman, T. Lee, M. Chau-wong, and K. Wong, Antipsychotic drug doses and neuroleptic/dopamine receptors, Nature, vol.16, issue.5562, pp.717-726, 1976.
DOI : 10.1002/cpt1972136931

P. Bret, F. Bonnet, M. Bret, J. A. Amisulpride, O. Clozapine et al., Use of atypical antipsychotics in Charles Perrens psychiatric hospital (Bordeaux) analysis of prescribing practices for, pp.329-371, 2002.

R. Kahn, W. Fleischhacker, H. Boter, M. Davidson, Y. Vergouwe et al., Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial, The Lancet, vol.371, issue.9618, pp.1085-97, 2008.
DOI : 10.1016/S0140-6736(08)60486-9

L. Ellinger, H. Ipema, and J. Stachnik, Efficacy of Metformin and Topiramate in Prevention and Treatment of Second-Generation Antipsychotic-Induced Weight Gain

D. Leslie and R. Rosenheck, Incidence of Newly Diagnosed Diabetes Attributable to Atypical Antipsychotic Medications, American Journal of Psychiatry, vol.161, issue.9, pp.1709-1720, 2004.
DOI : 10.1176/appi.ajp.161.9.1709

P. Juignet, Les effets indésirables des neuroleptiques

L. Schneider, P. Tariot, K. Dagerman, S. Davis, J. Hsiao et al., Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease, New England Journal of Medicine, vol.355, issue.15, pp.1525-1563, 2006.
DOI : 10.1056/NEJMoa061240

L. Zheng, W. Mack, K. Dagerman, J. Hsiao, B. Lebowitz et al., Metabolic Changes Associated With Second-Generation Antipsychotic Use in Alzheimer???s Disease Patients: The CATIE-AD Study, American Journal of Psychiatry, vol.166, issue.5, pp.583-90, 2009.
DOI : 10.1176/appi.ajp.2008.08081218

P. Falkai, Force on Treatment Guidelines for Schizophrenia traduction française par H. Verdoux, Recommandations pour le traitement biologique de la Schizophrénie Partie 2: Traitement à long terme de la Schizophrénie [Internet]. Available from

S. Leucht, C. Corves, D. Arbter, R. Engel, C. Li et al., Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis, The Lancet, vol.373, issue.9657, 2009.
DOI : 10.1016/S0140-6736(08)61764-X

J. Lieberman, T. Stroup, J. Mcevoy, M. Swartz, R. Rosenheck et al., Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia, New England Journal of Medicine, vol.353, issue.12, pp.1209-1232, 2005.
DOI : 10.1056/NEJMoa051688

P. Jones, T. Barnes, L. Davies, G. Dunn, H. Lloyd et al., Randomized Controlled Trial of the Effect on Quality of Life of Second- vs First-Generation Antipsychotic Drugs in Schizophrenia, Archives of General Psychiatry, vol.63, issue.10, pp.1079-87, 2006.
DOI : 10.1001/archpsyc.63.10.1079

S. Lewis, T. Barnes, L. Davies, R. Murray, G. Dunn et al., Randomized controlled trial of effect of prescription of clozapine versus other secondgeneration antipsychotic drugs in resistant schizophrenia, Schizophr Bull, 2006.

S. Leucht, K. Komossa, C. Rummel-kluge, C. Corves, H. Hunger et al., A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia, American Journal of Psychiatry, vol.166, issue.2, pp.152-63, 2009.
DOI : 10.1176/appi.ajp.2008.08030368

R. Buchanan, J. Kreyenbuhl, D. Kelly, J. Noel, D. Boggs et al., The 2009 Schizophrenia PORT Psychopharmacological Treatment Recommendations and Summary Statements, Schizophrenia Bulletin, vol.57, issue.8, pp.71-93, 2010.
DOI : 10.1176/appi.ps.57.8.1094

G. Alexander, S. Gallagher, A. Mascola, R. Moloney, and R. Stafford, Increasing offlabel use of antipsychotic medications in the United States, 1995.

B. René, Stimulation magnétique transcranienne répétée (rTMS) en psychiatrie : situation actuelle et perspectives

. Fondation-recherche-médicale, Schizophrénie [Internet]. 2012 Available from

C. Passerieux and N. Bazin, La re?e?ducation cognitive : e?valuation des re?sultats, Revue française des affaires sociales, pp.1-2, 2009.

V. Roder, D. Mueller, and S. Schmidt, Effectiveness of Integrated Psychological Therapy (IPT) for Schizophrenia Patients: A Research Update, Schizophrenia Bulletin, vol.19, issue.5, pp.71-79, 2011.
DOI : 10.1177/1049731509335561

A. Delahunty, R. Morice, and B. Frost, Specific cognitive flexibility rehabilitation in schizophrenia, Psychological Medicine, vol.38, issue.01, pp.221-228, 1993.
DOI : 10.1192/bjp.157.1.50

T. Wykes, C. Steel, B. Everitt, and N. Tarrier, Cognitive Behavior Therapy for Schizophrenia: Effect Sizes, Clinical Models, and Methodological Rigor, Schizophrenia Bulletin, vol.34, issue.3, 2008.
DOI : 10.1093/schbul/sbm114

M. Cartwright, S. Cohen, J. Fleishaker, S. Madani, J. Mcleod et al., Proof of Concept: A PhRMA Position Paper With Recommendations for Best Practice. Clin Pharmacol 38 Ther, pp.278-85, 2010.

M. Lapeyre-mestre, Placebo : De?finitions, inte?rêt, utilisation Master 2 pro : Pharmacologie et métiers du médicament, 2014.

R. Keefe, The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery, Schizophrenia Research, vol.68, issue.2-3, pp.2-3283, 2004.
DOI : 10.1016/j.schres.2003.09.011

M. Bralet, M. Navarre, A. Eskenazi, M. Lucas-ross, and B. Falissard, Inte?rêt d'un nouvel instrument dans l'e?valuation cognitive dans la schizophre?nie. L'Ence?phale, 2008.
DOI : 10.1016/j.encep.2007.12.005

M. Makdissi, C. A. Maruff, P. Darby, D. Bush, A. Mccrory et al., Computerised cognitive assessment of concussed Australian Rules footballers, British Journal of Sports Medicine, vol.35, issue.5, 2001.
DOI : 10.1136/bjsm.35.5.354

R. Pietrzak, J. Olver, T. Norman, D. Piskulic, P. Maruff et al., A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia, Journal of Clinical and Experimental Neuropsychology, vol.27, issue.7, pp.848-59, 2009.
DOI : 10.1016/j.neuropsychologia.2008.04.010

P. Maruff, E. Thomas, L. Cysique, B. Brew, C. A. Snyder et al., Validity of the CogState Brief Battery: Relationship to Standardized Tests and Sensitivity to Cognitive Impairment in Mild Traumatic Brain Injury, Schizophrenia, and AIDS Dementia Complex, Archives of Clinical Neuropsychology, vol.16, issue.7, pp.165-78, 2009.
DOI : 10.1093/arclin/16.7.653

D. Falconer, C. J. Fielding, S. Reid, and I. , Using the Cambridge Neuropsychological Test Automated Battery (CANTAB) to assess the cognitive impact of electroconvulsive therapy on visual and visuospatial memory, Psychological Medicine, vol.3, issue.06, pp.1017-1042, 2010.
DOI : 10.1080/01688638608405179

A. Vita, G. Deste, S. Barlati, D. Peri, L. Giambra et al., Interview-based assessment of cognition in schizophrenia: Applicability of the Schizophrenia Cognition Rating Scale (SCoRS) in different phases of illness and settings of care, Schizophrenia Research, vol.146, issue.1-3, pp.217-240, 2013.
DOI : 10.1016/j.schres.2013.02.035

T. Patterson, S. Goldman, C. Mckibbin, T. Hughs, and D. Jeste, UCSD Performance-Based Skills Assessment: Development of a New Measure of Everyday Functioning for Severely Mentally Ill Adults, Schizophrenia Bulletin, vol.27, issue.2, pp.235-280, 2001.
DOI : 10.1093/oxfordjournals.schbul.a006870

B. Mausbach, C. Bowie, P. Harvey, E. Twamley, S. Goldman et al., Usefulness of the UCSD performance-based skills assessment (UPSA) for predicting residential independence in patients with chronic schizophrenia, Journal of Psychiatric Research, vol.42, issue.4, 2008.
DOI : 10.1016/j.jpsychires.2006.12.008

S. E. Richard, ?. Keefe, K. Hurley-fox-b, P. D. Harvey-c, and J. Cucchiarod, Cynthia Siu e, Antony Loebel Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial, Schizophrenia Research, vol.125, pp.161-168, 2011.

N. Bakkour, J. Samp, K. Akhras, E. Hammi, E. Soussi et al., Systematic review of appropriate cognitive assessment instruments used in clinical trials of schizophrenia, major depressive disorder and bipolar disorder, Psychiatry Research, vol.216, issue.3, pp.291-302, 2014.
DOI : 10.1016/j.psychres.2014.02.014

R. Buchanan, R. Keefe, D. Umbricht, M. Green, T. Laughren et al., The FDA-NIMH-MATRICS Guidelines for Clinical Trial Design of Cognitive-Enhancing Drugs: What Do We Know 5 Years Later?, Schizophrenia Bulletin, vol.151, issue.1-2, pp.1209-1226, 2011.
DOI : 10.1016/j.psychres.2006.10.007

R. Buchanan, A Summary of the FDA-NIMH-MATRICS Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia, Schizophrenia Bulletin, vol.31, issue.1, pp.5-19, 2005.
DOI : 10.1093/schbul/sbi020

R. Keefe, R. Buchanan, S. Marder, N. Schooler, A. Dugar et al., Clinical Trials of Potential Cognitive-Enhancing Drugs in Schizophrenia: What Have We Learned So Far?, Schizophrenia Bulletin, vol.36, issue.2, pp.417-452, 2013.
DOI : 10.1038/npp.2010.193

R. Balzan, A. Neaves, L. Denson, D. Liu, and C. Galletly, Cognitive deficit awareness in schizophrenia: absent, intact, or somewhere in-between? Cognit Neuropsychiatry, 2014.

D. Barch, C. Carter, and . Cntrics-executive-committee, Measurement Issues in the Use of Cognitive Neuroscience Tasks in Drug Development for Impaired Cognition in Schizophrenia: A Report of the Second Consensus Building Conference of the CNTRICS Initiative, Schizophrenia Bulletin, vol.110, issue.1, pp.613-621, 2008.
DOI : 10.1037/0021-843X.110.1.15

C. Carter, D. Barch, R. Buchanan, E. Bullmore, J. Krystal et al., Identifying Cognitive Mechanisms Targeted for Treatment Development in Schizophrenia: An Overview of the First Meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative, Biological Psychiatry, vol.64, issue.1, pp.4-10, 2008.
DOI : 10.1016/j.biopsych.2008.03.020

C. Carter, D. Barch, and E. Bullmore, Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: Developing Imaging Biomarkers to Enhance Treatment Development for Schizophrenia and Related Disorders, Biological Psychiatry, vol.70, issue.1, pp.7-12, 2011.
DOI : 10.1016/j.biopsych.2011.01.041

D. Calderone, A. Martinez, V. Zemon, M. Hoptman, G. Hu et al., Comparison of psychophysical, electrophysiological, and fMRI assessment of visual contrast responses in patients with schizophrenia, NeuroImage, vol.67, pp.153-62, 2013.
DOI : 10.1016/j.neuroimage.2012.11.019

C. Scognamiglio and J. Houenou, A meta-analysis of fMRI studies in healthy relatives of patients with schizophrenia, Australian & New Zealand Journal of Psychiatry, vol.153, issue.10, 2014.
DOI : 10.3389/fpsyt.2013.00150

J. Furtner, D. Prayer, G. Sachs, M. Funktionelle, and . Schizophreniepatienten, Diagnostik und Therapiemonitoring kognitiver Defizite schizophrener Patienten mittels funktioneller MRT. Radiol, Feb, vol.50, issue.2, pp.131-136, 2010.

H. Möller, Novel antipsychotics and negative symptoms, International Clinical Psychopharmacology, vol.13, pp.43-47, 1998.
DOI : 10.1097/00004850-199803003-00008

S. Marder and B. Kirkpatrick, Defining and measuring negative symptoms of schizophrenia in clinical trials, European Neuropsychopharmacology, vol.24, issue.5, pp.737-780, 2014.
DOI : 10.1016/j.euroneuro.2013.10.016

S. Kay, A. Fiszbein, and L. Opler, The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia, Schizophrenia Bulletin, vol.13, issue.2, pp.261-76, 1987.
DOI : 10.1093/schbul/13.2.261

N. Andreasen, The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations, Br J Psychiatry, issue.7, pp.49-58, 1989.

L. Alphs, A. Summerfelt, H. Lann, and R. Muller, The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia, Psychopharmacol Bull, vol.25, issue.2, pp.159-63, 1989.

L. Alphs, R. Morlock, C. Coon, P. Cazorla, A. Szegedi et al., Validation of a 4-item Negative Symptom Assessment (NSA-4): a short, practical clinical tool for the assessment of negative symptoms in schizophrenia, International Journal of Methods in Psychiatric Research, vol.56, issue.2, pp.31-37, 2011.
DOI : 10.1016/S0920-9964(01)00161-X

B. Kirkpatrick, G. Strauss, L. Nguyen, B. Fischer, D. Daniel et al., The Brief Negative Symptom Scale: Psychometric Properties. Schizophr Bull, pp.300-305, 2011.
DOI : 10.1037/t28694-000

A. Kring, R. Gur, J. Blanchard, W. Horan, and S. Reise, The Clinical Assessment Interview for Negative Symptoms (CAINS): Final Development and Validation, American Journal of Psychiatry, vol.170, issue.2, p.165
DOI : 10.1176/appi.ajp.2012.12010109

B. Kirkpatrick, W. Fenton, W. Carpenter, . Jr, and S. Marder, The NIMH-MATRICS Consensus Statement on Negative Symptoms, Schizophrenia Bulletin, vol.30, issue.2, pp.214-223, 2006.
DOI : 10.1016/0165-1781(89)90153-4

S. Marder, D. Daniel, L. Alphs, A. Awad, and R. Keefe, Methodological Issues in Negative Symptom Trials, Schizophrenia Bulletin, vol.32, issue.2, pp.250-254, 2011.
DOI : 10.1093/schbul/sbj013

N. Tarrier, Negative Symptoms in Schizophrenia: Comments From a Clinical Psychology Perspective, Schizophrenia Bulletin, vol.155, issue.3, pp.231-234, 2006.
DOI : 10.1176/ajp.155.3.350